{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:51Z","timestamp":1792178991875,"version":"4.4.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["950584"],"award-info":[{"award-number":["950584"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RFA-2203-39300"],"award-info":[{"award-number":["RFA-2203-39300"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["GRK 2727"],"award-info":[{"award-number":["GRK 2727"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["11-1"],"award-info":[{"award-number":["11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["FOR 2690"],"award-info":[{"award-number":["FOR 2690"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SPP 2395"],"award-info":[{"award-number":["SPP 2395"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SCHI 1330\/2-1"],"award-info":[{"award-number":["SCHI 1330\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017325","name":"Engineering Research Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.tips.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:08:28Z","timestamp":1739261308000},"page":"249-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Emerging mechanisms and therapeutics in inflammatory muscle diseases"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-1196","authenticated-orcid":false,"given":"Sven","family":"Wischnewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-843X","authenticated-orcid":false,"given":"Hans-Werner","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-1696","authenticated-orcid":false,"given":"Chiseko","family":"Ikenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-9700","authenticated-orcid":false,"given":"Jan","family":"Leipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-3700","authenticated-orcid":false,"given":"Thomas E.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-4116","authenticated-orcid":false,"given":"Lucas","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.01.005_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","article-title":"Dermatomyositis: an update on diagnosis and treatment","volume":"21","author":"Cobos","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0025","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin. Pulm. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0035","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","article-title":"Myositis as a neuromuscular complication of immune checkpoint inhibitors","volume":"120","author":"Vermeulen","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.tips.2025.01.005_bb0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress \u2013 revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.tips.2025.01.005_bb0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0060","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.tips.2025.01.005_bb0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-021-01017-7","article-title":"Updates on the immunopathology in idiopathic inflammatory myopathies","volume":"23","author":"Uruha","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.tips.2025.01.005_bb0070","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neurol.2024.09.003","article-title":"Inflammatory myopathies in 2024: better classify them to better treat them","volume":"180","author":"Benveniste","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.tips.2025.01.005_bb0075","doi-asserted-by":"crossref","first-page":"e1374","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","volume":"98","author":"Goyal","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.autrev.2019.02.003","article-title":"CD8+ cells as a predominant biomarker for inclusion body myositis","volume":"18","author":"Dzangu\u00e9-Tchoupou","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2025.01.005_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1504","article-title":"Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models","volume":"13","author":"McLeish","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0090","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ni1268","article-title":"Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin","volume":"6","author":"Intlekofer","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/imt.10.111","article-title":"More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases","volume":"3","author":"Ji","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.tips.2025.01.005_bb0100","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.4049\/jimmunol.0804308","article-title":"Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice","volume":"183","author":"Kim","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.01.005_bb0110","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.11063","article-title":"CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis","volume":"48","author":"Morgan","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.26304","article-title":"Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis","volume":"91","author":"Ikenaga","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2025.01.005_bb0125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0130","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2025.01.005_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.tips.2025.01.005_bb0145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0150","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0160","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2025.01.005_bb0165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0170","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.01.005_bb0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","article-title":"Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis","volume":"20","author":"Ishikawa","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2025.01.005_bb0180","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0185","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.tips.2025.01.005_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13155","article-title":"Muscle pathology of antisynthetase syndrome according to antibody subtypes","volume":"33","author":"Tanboon","year":"2023","journal-title":"Brain Pathol."},{"key":"10.1016\/j.tips.2025.01.005_bb0200","article-title":"Single-cell transcriptomics reveals peripheral immune responses in anti-synthetase syndrome-associated interstitial lung disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0205","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0210","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/25785826.2024.2336687","article-title":"Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature","volume":"47","author":"Yamazaki","year":"2024","journal-title":"Immunol. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0215","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kead404","article-title":"Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients","volume":"63","author":"Beckett","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0220","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.tips.2025.01.005_bb0225","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0230","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP and anti-HMGCR myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0235","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0245","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.01.005_bb0255","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0260","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis","volume":"20","author":"Kry\u0161t\u016ffkov\u00e1","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2025.01.005_bb0265","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0270","doi-asserted-by":"crossref","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","article-title":"Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis","volume":"40","author":"Salam","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0275","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0280","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acn3.51294","article-title":"Clinical utility of anti-cytosolic 5\u2019-nucleotidase 1A antibody in idiopathic inflammatory myopathies","volume":"8","author":"Ikenaga","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0285","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/mus.27157","article-title":"Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","volume":"63","author":"Paul","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2025.01.005_bb0290","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5\u2019-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0295","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/jnnp-2023-331474","article-title":"Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis","volume":"94","author":"Yamashita","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2025.01.005_bb0300","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0305","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0310","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0315","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0320","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.tips.2025.01.005_bb0325","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0330","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2025.01.005_bb0335","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.01.005_bb0340","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0345","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.tips.2025.01.005_bb0350","first-page":"460","article-title":"Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab","volume":"42","author":"Chua","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003238","article-title":"Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.tips.2025.01.005_bb0360","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/ard-2022-223541","article-title":"Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy","volume":"82","author":"Landon-Cardinal","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.01.005_bb0365","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0370","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H antihistamine-refractory chronic spontaneous urticaria: a randomized Phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000001269","article-title":"Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations","volume":"37","author":"Kr\u00e4mer","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0380","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, Phase II trial (ANDES Study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113313","article-title":"Zanubrutinib ameliorates experimental idiopathic inflammatory myopathy-associated interstitial lung disease by BTK\/NF-\u03baB signaling pathway","volume":"143","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2025.01.005_bb0390","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.01.005_bb0395","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0400","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.01.005_bb0405","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2025.01.005_bb0410","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a Phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0420","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13238-012-2105-7","article-title":"Functional characterization of SAG\/RBX2\/ROC2\/RNF7, an antioxidant protein and an E3 ubiquitin ligase","volume":"4","author":"Sun","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.tips.2025.01.005_bb0425","doi-asserted-by":"crossref","first-page":"351","DOI":"10.55563\/clinexprheumatol\/6mp37n","article-title":"Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies","volume":"39","author":"Milisenda","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","article-title":"Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies","volume":"30","author":"Fischer","year":"2020","journal-title":"Brain Pathol."},{"key":"10.1016\/j.tips.2025.01.005_bb0435","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s43587-024-00645-9","article-title":"Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis","volume":"4","author":"Wischnewski","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.tips.2025.01.005_bb0440","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-019-04314-8","article-title":"Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature","volume":"39","author":"Papadimas","year":"2019","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.tips.2025.01.005_bb0445","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.aab0983","article-title":"TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD","volume":"349","author":"Ling","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.01.005_bb0450","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00401-017-1701-2","article-title":"Cryptic exon incorporation occurs in Alzheimer\u2019s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43","volume":"133","author":"Sun","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2025.01.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7162","article-title":"Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS\/FTD","volume":"16","author":"Seddighi","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0460","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","article-title":"A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD","volume":"30","author":"Irwin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0465","doi-asserted-by":"crossref","first-page":"e2212","DOI":"10.1212\/WNL.0000000000201103","article-title":"Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis","volume":"99","author":"Kleefeld","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0470","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149381","article-title":"GADD45A is a protective modifier of neurogenic skeletal muscle atrophy","volume":"6","author":"Ehmsen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.01.005_bb0475","doi-asserted-by":"crossref","first-page":"E907","DOI":"10.1152\/ajpendo.00380.2013","article-title":"Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4","volume":"305","author":"Bongers","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.01.005_bb0480","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1210\/me.2009-0345","article-title":"The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting","volume":"24","author":"Ebert","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tips.2025.01.005_bb0485","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.21230","article-title":"Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis","volume":"39","author":"Parker","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2025.01.005_bb0490","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00401-023-02637-2","article-title":"Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis","volume":"146","author":"Nelke","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2025.01.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153837","article-title":"Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy","volume":"133","author":"Russell","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.01.005_bb0500","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.nmd.2022.07.240","article-title":"P.124 EDG-5506 targets fast skeletal myosin and reduces muscle damage biomarkers in a phase 1 trial in Becker muscular dystrophy (BMD)","volume":"32","author":"Donovan","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.tips.2025.01.005_bb0505","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/nar\/gkx1120","article-title":"Identification of diverse target RNAs that are functionally regulated by human Pumilio proteins","volume":"46","author":"Bohn","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2025.01.005_bb0510","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-021-03633-w","article-title":"NORAD-induced Pumilio phase separation is required for genome stability","volume":"595","author":"Elguindy","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.01.005_bb0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2015.12.017","article-title":"Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins","volume":"164","author":"Lee","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.01.005_bb0520","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.tips.2025.01.005_bb0525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cbi.2010.03.034","article-title":"Acetylcholinesterase is involved in apoptosis in the precursors of human muscle regeneration","volume":"187","author":"Pegan","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tips.2025.01.005_bb0530","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnmol.2012.00040","article-title":"Acetylcholinesterase involvement in apoptosis","volume":"5","author":"Zhang","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.tips.2025.01.005_bb0535","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","article-title":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","volume":"32","author":"Remijn-Nelissen","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.tips.2025.01.005_bb0540","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics \u2013 challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.01.005_bb0545","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","article-title":"Therapeutic targeting of long non-coding RNAs in cancer","volume":"24","author":"Arun","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2025.01.005_bb0550","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0555","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled Phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0560","doi-asserted-by":"crossref","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","article-title":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis","volume":"95","author":"Sivakumar","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0565","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2025.01.005_bb0570","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, Phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0575","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/jcsm.13451","article-title":"Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy","volume":"15","author":"Reyngoudt","year":"2024","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.tips.2025.01.005_bb0580","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome \u2013 much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.01.005_bb0585","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","article-title":"Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases","volume":"147","author":"Nelke","year":"2024","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2025.01.005_bb0590","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0595","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2025.01.005_bb0600","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.01.005_bb0605","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1212\/WNL.0000000000013176","article-title":"Dermatomyositis: muscle pathology according to antibody subtypes","volume":"98","author":"Tanboon","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2025.01.005_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun. Rev."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:09:49Z","timestamp":1741262989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0165614725000057"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.01.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging mechanisms and therapeutics in inflammatory muscle diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}